Inmagene's OX40 mAb, with an extended half-life and silenced

Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis

Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis
singaporestar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from singaporestar.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Sydney , New South Wales , Australia , Shanghai , China , Yufang Lu , , Inmagene Biopharmaceuticals , Chief Medical Officer , Atopic Dermatitis , Allergy Asthma Immunol ,